Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more
Pharma Reaserch Prod Co Ltd (214450) - Total Liabilities
Latest total liabilities as of September 2025: ₩299.53 Billion KRW
Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) has total liabilities worth ₩299.53 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharma Reaserch Prod Co Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Pharma Reaserch Prod Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharma Reaserch Prod Co Ltd Competitors by Total Liabilities
The table below lists competitors of Pharma Reaserch Prod Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Isiklar Enerji ve Yapi Holding AS
IS:IEYHO
|
Turkey | TL1.35 Billion |
|
Tsubakimoto Chain Co
F:TSB
|
Germany | €110.82 Billion |
|
China Cinda Asset Management Co., Ltd.
F:0CI
|
Germany | €1.46 Trillion |
|
Hunan Valin Steel Co Ltd
SHE:000932
|
China | CN¥85.51 Billion |
|
LG Display Co Ltd
NYSE:LPL
|
USA | $19.08 Trillion |
|
Shenzhen Overseas Chinese Town Co Ltd
SHE:000069
|
China | CN¥239.22 Billion |
|
Imdex Limited
F:IDG
|
Germany | €200.79 Million |
|
Beijing Worldia Diamond Tools Co Ltd
SHG:688028
|
China | CN¥290.44 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Pharma Reaserch Prod Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharma Reaserch Prod Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharma Reaserch Prod Co Ltd (2015–2024)
The table below shows the annual total liabilities of Pharma Reaserch Prod Co Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩286.26 Billion | +291.67% |
| 2023-12-31 | ₩73.09 Billion | -45.68% |
| 2022-12-31 | ₩134.55 Billion | +10.10% |
| 2021-12-31 | ₩122.20 Billion | +64.23% |
| 2020-12-31 | ₩74.41 Billion | +22.28% |
| 2019-12-31 | ₩60.85 Billion | +0.47% |
| 2018-12-31 | ₩60.56 Billion | +494.87% |
| 2017-12-31 | ₩10.18 Billion | +32.38% |
| 2016-12-31 | ₩7.69 Billion | -38.76% |
| 2015-12-31 | ₩12.56 Billion | -- |